A novel vaccine: botulinum neurotoxin subunit on a viral carrier.

描述（由申请人提供）：根据NIAID关于肉毒杆菌中毒的情况说明书，“肉毒杆菌神经毒素（BoNT）的极端毒性以及生产、运输和交付的便利性使其成为极端生物恐怖主义关注的物质。“尽管如此，尽管正在进行重大的疫苗开发计划，但目前还没有批准的肉毒杆菌毒素疫苗。植物毒素研究的进展已经指定疫苗开发的最佳靶点是毒素重链的无毒羧基末端的一半（HC 50）。事实上，NIAID的一个直接研究目标被列为开发针对肉毒杆菌的HC50片段疫苗。 基于该项目第一阶段概念验证研究的令人鼓舞的数据，第二阶段项目的总体目标是开发一种针对最常见血清型A、B和E的新的三价肉毒杆菌疫苗。提出了进一步开发这种新型三价BoNT疫苗的三个目标，如下：具体目标1：疫苗载体构建和回收。i）质粒构建，ii）BoNT HC50的细胞表面表达的证明，和iii）在Vero上从cDNA再回收重组RV。具体目标2。疫苗载体表征i）RV病毒粒子的纯化、灭活和体外表征，ii）使用ELISA、体外中和测定和体内保护小鼠免受BoNT单次攻击或多次BoNT攻击（取决于用于免疫的疫苗）分析小鼠对疫苗的免疫应答。具体目标3：开发中试生产和纯化工艺。这一目标的总体目标是将我们疫苗的生产工艺从研究环境转化为适合中试规模疫苗生产的生产工艺。

DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, "the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern." Nonetheless, although there are major vaccine development initiatives ongoing, there currently is no approved Botulinum toxin vaccine available. Advances in Botulinum research have designated the optimal target for vaccine development to be the non-toxic carboxyterminal half of the toxin heavy chain (HC50). In fact, an immediate research goal for NIAID is listed as the development of a HC50 fragment vaccine against botulinum. Building upon the encouraging data from the phase I proof of concept study of this project, the overall phase II project goal is to develop a new, trivalent botulinum vaccine against the most common serotypes A, B and E. Three Aims are proposed for the further development of this novel trivalent BoNT vaccine as follows: Specific Aim 1: Vaccine vector construction and recovery. i) plasmid constructions, ii) demonstration of cell surface expression of the BoNT HC50, and iii) re-recovery of recombinant RVs from cDNA on Vero. Specific Aim 2. Vaccine vector characterization i) purification, inactivation, and in vitro characterization of the RV virions, ii) analysis of mouse immune responses to the vaccine using ELISA, in vitro neutralization assays, and in vivo protection of mice against a single challenge with BoNT or multiple BoNT challenge dependent on the used vaccine(s) for immunization. Specific Aim 3: Development of Pilot Production and Purification Processes. The overall goal of this aim is to translate the production process of our vaccine from a research setting to one suitable for pilot scale vaccine manufacture.